About Biologic Therapeutics
Biologic therapeutics include virus, therapeutic serum, toxin, allergenic product, antitoxin, blood component or derivative, vaccine, blood, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), intended for the prevention, treatment, or cure of a disease or condition. These products differ from small molecules in terms of molecular weight, structure, synthesis, and immunogenicity. Biologic products are generally characterized by high molecular weight and complex structures. These products are usually derived from living entities and are less easily characterized compared to small molecules. These products are often susceptible to extreme temperatures and light.
TechNavio's analysts forecast the Global Biologic Therapeutics market to grow at a CAGR of 8.22 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Biologic Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of the following drugs:
• Protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics)
• Vaccines (pediatric vaccines and adult vaccines)
• Cell therapy
The Other Protein Therapeutics segment covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.
TechNavio's report, Global Biologic Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Biologic Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Amgen
• F. Hoffmann-La Roche
• Novo Nordisk
• Sanofi
Other Prominent Vendors
• Abbvie
• AstraZeneca
• Bavarian Nordic
• Baxter International
• Beijing Minhai Biotechnology
• Bharat Biotech
• Bharat Immunologicals and Biologicals
• bioCSL
• Biodel
• Bio Med
• Bristol-Myers Squibb
• Diamyd Medical
• DiaVacs
• Dynavax Technologies
• Eli Lilly
• Generex Biotechnology
• Hualan Biological Engineering
• Imunoloski Zavod
• Indian Immunologicals
• Janssen Pharmaceuticals
• JN International Medical
• Kaketsuken
• LG Life Sciences
• Macrogenics
• MannKind
• Merck & Co.
• Mitsubishi Tanabe Pharma
• Nuron Biotech
• Osiris Therapeutics
• Pfizer
• Protalix
• Protein Sciences
• Serum Institute of India
• Shenzhen Kangtai Biological Products
• Sinovac Biotech
• Tolerion
• Vacunas Finlay
• XOMA
• Zydus Cadila
Market Driver
• Aging Population
• For a full, detailed list, view our report
Market Challenge
• Requirement of Cold Storage
• For a full, detailed list, view our report
Market Trend
• Emergence of Targeted and Combination Therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Molecule Type
08. Geographical Segmentation
09. Buying Criteria
10. Global Protein Therapeutics Market
10.1 Introduction
10.2 Drivers, Challenges and Trends
10.3 Market Size and Forecast
10.4 Market Segmentation by Molecule Type
10.4.1 Global Monoclonal Antibodies Market
10.4.2 Global Enzymes Market
10.4.3 Global Other Protein Therapeutics Market
11. Global Vaccines Market
11.1 Introduction
11.2 Drivers, Challenges and Trends
11.3 Market Size and Forecast
11.4 Market Segmentation by Composition
11.5 Market Segmentation by End-user Age Group
11.5.1 Global Pediatric Vaccines Market
11.5.2 Global Adult Vaccines Market
12. Global Cell Therapy Market
12.1 Introduction
12.2 Drivers, Challenges and Trends
12.3 Market Size and Forecast
13. Market Growth Drivers
13.1.1 Overall Market Drivers
13.1.2 Segment Specific Drivers
14. Drivers and their Impact
15. Market Challenges
15.1.1 Overall Market Challenges
15.1.2 Segment Specific Challenges
16. Impact of Drivers and Challenges
17. Market Trends
17.1.1 Overall Market Trends
17.1.2 Segment Specific Trends
18. Trends and their Impact
19. Competitive Scenario
19.1 Key News
19.2 Mergers and Acquisitions
20. Market Share Analysis 2013
20.1 Market Snapshot of Top Vendors
20.2 Market Share of Key Vendors
20.3 Market Forecast of Key Vendors
20.3.1 F. Hoffmann-La Roche
20.3.2 Sanofi
20.3.3 Amgen
20.3.4 Novo Nordisk
21. Market Assessment of Major Biologic Therapeutics of Key Vendors
21.1 F. Hoffmann-La Roche
21.1.1 Avastin
21.1.2 Herceptin
21.1.3 Kadcyla
21.1.4 Lucentis
21.1.5 MabThera/Rituxan
21.1.6 Pegasys
21.1.7 Perjeta
21.2 Sanofi
21.2.1 Aldurazyme
21.2.2 Cerezyme
21.2.3 Fabrazyme
21.2.4 Myozyme/Lumizyme
21.2.5 Lantus
21.3 Amgen
21.3.1 Enbrel
21.3.2 Neulasta
21.3.3 Xgeva/Prolia
21.4 Novo Nordisk
21.4.1 NovoRapid/NovoLog
21.4.2 Victoza
21.5 Other Prominent and Future Vendors
22. Key Vendor Analysis
22.1 Amgen
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation by Revenue 2013
22.1.4 Sales by Geographical Segmentation 2013
22.1.5 Business Strategy
22.1.6 Key Information
22.1.7 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Geographical Segmentation by Revenue
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.3 Novo Nordisk A/S
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation
22.3.4 Business Strategy
22.3.5 Revenue Segmentation by Business
22.3.6 Revenue Comparison by Business Segments 2012 and 2013
22.3.7 Sales by Geography
22.3.8 Key Information
22.3.9 SWOT Analysis
22.4 Sanofi
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Geographical Segmentation by Revenue 2013
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Biologic Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Global Biologic Therapeutics Market Segmentation by Molecule Type
Exhibit 4: Global Biologic Therapeutics Market by Molecule Type 2013
Exhibit 5: Global Biologic Therapeutics Market by Molecule Type 2018
Exhibit 6: Global Biologic Therapeutics Market by Molecule Type 2013-2018 (US$ billion)
Exhibit 7: Global Biologic Therapeutics Market by Molecule Type 2013-2018
Exhibit 8: Global Biologic Therapeutics Market Segments 2013-2018
Exhibit 9: YoY Growth Rate of Global Biologic Therapeutics Market Segments 2013-2018
Exhibit 10: Global Biologic Therapeutics Market Segmentation by Geography 2013
Exhibit 11: Key Factors Influencing the Global Protein Therapeutics Market
Exhibit 12: Global Protein Therapeutics Market Key Trends
Exhibit 13: Global Protein Therapeutics Market 2013-2018 (US$ billion)
Exhibit 14: Global Protein Therapeutics Market by Molecule Type
Exhibit 15: Global Protein Therapeutics Market by Molecule Type 2013
Exhibit 16: Global Protein Therapeutics Market by Molecule Type 2018
Exhibit 17: Global Protein Therapeutics Market by Molecule Type 2013-2018 (US$ billion)
Exhibit 18: Global Protein Therapeutics Market by Molecule Type 2013-2018
Exhibit 19: Global Protein Therapeutics Market Segmentation 2013-2018
Exhibit 20: YoY Growth Rate of Global Protein Therapeutics Market Segments 2013-2018
Exhibit 21: Global Monoclonal Antibodies Market 2013-2018 (US$ billion)
Exhibit 22: Global Enzymes Market 2013-2018 (US$ billion)
Exhibit 23: Global Other Protein Therapeutics Market 2013-2018 (US$ billion)
Exhibit 24: Global Vaccines Market Drivers
Exhibit 25: Global Vaccines Market Challenges
Exhibit 26: Global Vaccines Market Trends
Exhibit 27: Global Vaccines Market 2013-2018 (US$ billion)
Exhibit 28: Global Vaccines Market Segmentation by Vaccine Type
Exhibit 29: Global Vaccines Market Segmentation by End-user Age Group
Exhibit 30: Global Vaccines Market Segmentation by End-user Age Group 2013
Exhibit 31: Global Vaccines Market Segmentation by End-user Age Group 2018
Exhibit 32: Global Vaccines Market Segmentation by End-user Age Group 2013-2018 (US$ billion)
Exhibit 33: Global Vaccines Market Segmentation by End-user Age Group 2013-2018
Exhibit 34: Global Vaccines Market Segmentation 2013-2018
Exhibit 35: YoY Growth Rate of Global Vaccines Market Segments 2013-2018
Exhibit 36: Global Pediatric Vaccines Market 2013-2018 (US$ billion)
Exhibit 37: Global Adult Vaccines Market 2013-2018 (US$ billion)
Exhibit 38: Key Factors Influencing the Global Cell Therapy Market
Exhibit 39: Global Cell Therapy Market 2013-2018 (US$ billion)
Exhibit 40: Global Biologic Therapeutics Market Drivers
Exhibit 41: Global Biologic Therapeutics Overall Market Drivers
Exhibit 42: World's Population Aged 60 and Above 2010-2020 (billion)
Exhibit 43: Global Biologic Therapeutics Segment Specific Drivers
Exhibit 44: Incidence and Prevalence of Type 1 Diabetes in Children (0-14 Years) 2013 (in thousands)
Exhibit 45: Global Biologic Therapeutics Market Challenges
Exhibit 46: Global Biologic Therapeutics Overall Market Challenges
Exhibit 47: Global Biologic Therapeutics Segment Specific Challenges
Exhibit 48: Global Biologic Therapeutics Market Trends
Exhibit 49: Global Biologic Therapeutics Market General Trends
Exhibit 50: Global Biologic Therapeutics Segment Specific Trends
Exhibit 51: Market Statistics for Key Vendors in Global Biologic Therapeutics Market
Exhibit 52: Global Biologic Therapeutics Market Share Analysis 2013
Exhibit 53: Global Biologic Therapeutics Market Share Analysis 2018
Exhibit 54: Global Biologic Therapeutics Market Share Analysis of Key Vendors 2013
Exhibit 55: Global Biologic Therapeutics Market Share Analysis of Key Vendors 2018
Exhibit 56: YoY Growth Rate of Key Vendors in the Global Biologic Therapeutics Market
Exhibit 57: F. Hoffmann-La Roche Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 58: Sanofi Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 59: Amgen Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 60: Novo Nordisk Biologic Therapeutics Market Size and Forecast 2013-2018 (US$ billion)
Exhibit 61: Revenue of Major Biologic Therapeutics of Key Vendors
Exhibit 62: F. Hoffmann-La Roche: Market Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 63: Geography-wise Segmentation of Avastin 2013 (US$ million)
Exhibit 64: Geography-wise Segmentation of Avastin 2013
Exhibit 65: Avastin Market Size and Forecast 2013-2018 (US$ million)
Exhibit 66: Geography-wise Segmentation of Herceptin 2013 (US$ million)
Exhibit 67: Geography-wise Segmentation of Herceptin 2013
Exhibit 68: Herceptin Market Size and Forecast 2013-2018 (US$ million)
Exhibit 69: Geography-wise Segmentation of Kadcyla 2013 (US$ million)
Exhibit 70: Geography-wise Segmentation of Kadcyla 2013
Exhibit 71: Kadcyla Market Size and Forecast 2013-2018 (US$ million)
Exhibit 72: Timeline of Key Regulatory Approvals of Lucentis
Exhibit 73: Lucentis Sales by Geographical Segmentation 2006-2013 (US$ million)
Exhibit 74: Lucentis Revenue 2006-2013 (US$ million)
Exhibit 75: Geography-wise Segmentation of MabThera/Rituxan 2013 (US$ million)
Exhibit 76: Geography-wise Segmentation of MabThera/Rituxan 2013
Exhibit 77: MabThera/Rituxan Market Size and Forecast 2013-2018 (US$ million)
Exhibit 78: Geography-wise Segmentation of Pegasys 2013 (US$ million)
Exhibit 79: Geography-wise Segmentation of Pegasys 2013
Exhibit 80: Geography-wise Segmentation of Perjeta 2013 (US$ million)
Exhibit 81: Geography-wise Segmentation of Perjeta 2013
Exhibit 82: Perjeta Market Size and Forecast 2013-2018 (US$ million)
Exhibit 83: SanofI: Market Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 84: Geography-wise Segmentation of Aldurazyme 2013 (US$ million)
Exhibit 85: Geography-wise Segmentation of Aldurazyme 2013
Exhibit 86: Geography-wise Segmentation of Cerezyme 2013 (US$ million)
Exhibit 87: Geography-wise Segmentation of Cerezyme 2013
Exhibit 88: Geography-wise Segmentation of Fabrazyme 2013 (US$ million)
Exhibit 89: Geography-wise Segmentation of Fabrazyme 2013
Exhibit 90: Geography-wise Segmentation of Myozyme/Lumizyme 2013 (US$ million)
Exhibit 91: Geography-wise Segmentation of Myozyme/Lumizyme 2013
Exhibit 92: Geography-wise Segmentation of Lantus 2013 (US$ million)
Exhibit 93: Geography-wise Segmentation of Lantus 2013
Exhibit 94: Lantus Market Size and Forecast 2013-2018 (US$ million)
Exhibit 95: Geography-wise Segmentation of Enbrel 2013 (US$ million)
Exhibit 96: Geography-wise Segmentation of Enbrel 2013
Exhibit 97: Enbrel Market Size and Forecast 2013-2018 (US$ million)
Exhibit 98: Geography-wise Segmentation of Neulasta 2013 (US$ million)
Exhibit 99: Geography-wise Segmentation of Neulasta 2013
Exhibit 100: Neulasta Market Size and Forecast 2013-2018 (US$ million)
Exhibit 101: Geography-wise Segmentation of Xgeva/Prolia 2013 (US$ million)
Exhibit 102: Geography-wise Segmentation of Xgeva/Prolia 2013
Exhibit 103: Xgeva/Prolia Market Size and Forecast 2013-2018 (US$ million)
Exhibit 104: Market Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 105: Geography-wise Sales for Key Biologic Therapeutics 2013 (US$ million)
Exhibit 106: Geography-wise Segmentation of NovoRapid/NovoLog 2013 (US$ million)
Exhibit 107: Geography-wise Segmentation of NovoRapid/NovoLog 2013
Exhibit 108: NovoRapid/NovoLog Market Size and Forecast 2013-2018 (US$ million)
Exhibit 109: Geography-wise Segmentation of Victoza 2013 (US$ million)
Exhibit 110: Geography-wise Segmentation of Victoza 2013
Exhibit 111: Victoza Market Size and Forecast 2013-2018 (US$ million)
Exhibit 112: Amgen: Product Segmentation by Revenue 2013
Exhibit 113: Amgen: Sales by Geographical Segmentation 2013
Exhibit 114: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 115: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 116: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 117: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 118: Business Segments of Novo Nordisk A/S 2013
Exhibit 119: Novo Nordisk A/S: Business Segmentation 2013
Exhibit 120: Novo Nordisk A/S: Revenue Comparison 2012 and 2013 (US$ million)
Exhibit 121: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 122: Sanofi: Business Segmentation by Revenue 2013
Exhibit 123: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 124: Sanofi: Geographical Segmentation by Revenue 2013
